Peder Sven Walberg

Peder Sven Walberg was the founder of Wilson Therapeutics AB, founded in 2012, where the title held was Director from 2012 to 2015.
Dr. Walberg was the founder of Rare Thyroid Therapeutics International AB, founded in 2017, where the title held was Chief Executive Officer & Director from 2017 to 2020.
Dr. Walberg is also the founder of Immedica Pharma AB..
Dr. Walberg is currently Chief Executive Officer & Director at Cetoros AB, Chairman & Chief Executive Officer at TTM HoldCo AB, Director at Immedica Pharma Holding AB, and Director at Akiram Therapeutics AB. Former positions include Director at OxThera AB from 2011 to 2016, Director at Egetis Therapeutics AB from 2021 to 2024, Head-Business Development & Licensing at Novartis AG from 2005 to 2007, Management & Strategy Consultant at The Boston Consulting Group, Inc., EVP-Business Development & Strategy at Swedish Orphan International Holding AB, and EVP-Business Development & Strategy at Swedish Orphan Biovitrum AB from 2010 to 2011.
Education includes undergraduate and doctorate degrees from the University of Uppsala and an undergraduate degree from the Swedish Armed Forces Language Institute.